New Agreements Result in Removal of Two Affiliated Utilities & Parent Company from Company’s 2024 Iowa Patent Litigation CORSICANA, Texas, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Birchtech Corp. (TSX: BCHT) (OTCQB: BCHT) ("Birchtech" or the "Company"), a leader in specialty activated carbon technologies for sustainable air and water treatment, today announced non-exclusive agreements with two coal-fired power utilities, affiliated with one another, named as defendants in the Company’s July 2024 lawsuit filed in ...

DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel II, CFO, will participate in the upcoming September conferences: H.C. Wainwright 27th Annual Global Investment Conference and the Investor Summit Group Q3 Virtual Conference. Investor Conference Details: H.C ...

New York, NY, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Globalink Investment Inc. (OTC Pink: GLLI, GLLIW, GLLIR, GLLIU) (“Globalink” or the “Company”), a special purpose acquisition company, announced today that on September 4, 2025, it caused to be deposited $0.15 per public share, totaling $10,890.15 (the “Extension Payment”) into its trust account (the “Trust Account”) with Continental Stock Transfer and Trust Company (“Continental”) to extend the deadline to complete its initial business combination from Septe ...

EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; Cortical Improvements Comparable to Injectable Teriparatide and Abaloparatide Company Plans to Initiate Global Registrational Phase 3 Study Following July 2025 FDA Concurrence Entera also Presented Promising Pharmacokinetic Data for Next-Gen EB613 Single Tablet Candidate as Potential Future Franchise Extension JERUSALEM, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Lt ...

ATHENS, Greece, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Dynagas LNG Partners LP (NYSE: “DLNG”) (the “Partnership”), an owner and operator of liquefied natural gas (“LNG”) carriers, today announced its results for the three and six months ended June 30, 2025. Half year Highlights: Net Income and Earnings per common unit (basic and diluted) of $27.3 million and $0.52, respectively;Adjusted Net Income(1) of $28.8 million and Adjusted Earnings per common unit(1) (basic and diluted) of $0.56;Adjusted EBITDA(1) of $5 ...

OLD GREENWICH, Conn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (Nasdaq: STRR and STRRP) (“Star” or the “Company”), a diversified holding company, announced today that its wholly owned subsidiary, Hudson RPO, operating inside its Business Services division, has rebranded to Hudson Talent Solutions (“HTS”), reflecting the business’ broadened vision and expanded global capabilities. The rebrand is accompanied by the launch of a new website, www.hudsontalent.com. The change is the culminati ...

Determined that Wellspect will Deliver Greater Financial and Strategic Benefits to Stockholders as Part of the CompanyCHARLOTTE, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company has completed the evaluation of strategic alternatives for its Wellspect Healthcare business (“Wellspect”), which was announced in February 2025. As a part of its review process, Dentsply Sirona considered a range of potential opportuni ...

Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that it has enrolled the first two subjects, and treated one, in the European Union (EU) in its pivotal Phase 2B/3, ...

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA feedback from Type D meeting expected by end of September THE WOODLANDS, Texas, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Company has submitted additional clinical data to the U.S. Food and Drug Adminis ...

NEW PORT RICHEY, Fla., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Zeo Energy Corp. (Nasdaq: ZEO) (“Zeo,” “Zeo Energy,” or the “Company”), a Florida-based provider of residential solar and commercial long-duration energy-storage solutions, today announced that the Company will be presenting at ROTH Capital’s 12th Annual Solar & Storage Symposium on Tuesday, September 9, at the upcoming RE+ trade show in Las Vegas, Nevada, which runs from September 8-11, 2025. The symposium, hosted by ROTH Capital during RE+, provide ...